MedProduct,ActiveSub,firstPediatricDate,Orphan,TherapeuticArea,ATC,MainCondition,MinimumApprovedAge,PediatricTherapeuticIndications,elabSMILES,prediction
Abilify,aripiprazole,2009,no,Neurology,N- Neuropsychiatric,Bipolar Disorder Schizophrenia,> 13 years,  (Bipolar I Disorder),O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1
Abraxane,paclitaxel,2020,no,Oncology ,L- Antineoplastic and immunomodulating,nd,nd,_PIP negative outcome,CC(=O)OC1=C2C(C)C(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)CC(O)(C(OC(=O)c3ccccc3)C3C4(OC(C)=O)COC4CC(O)C3(C)C1=O)C2(C)C,1
Baraclude,Entecavir,2014,no,Infectious diseases,J- Antiinfectives,"Hepatitis B, Chronic",> 2 years,"Baraclude is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to < 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. ",C=C1C(CO)C(O)CC1n1cnc2c(=O)[nH]c(N)nc21,1
Bemrist Breezhaler,"indacaterol, Mometasone furoate",2020,no,Respiratory ,R- Respiratory,Asthma,> 12 years,Bemrist Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.,CC1CC2C3CC=C4CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(OC(=O)c1ccco1)C(=O)CCl,1
Briviact (in Italy: Nubriveo),Brivaracetam,2016,no,Neurology,N- Neuropsychiatric,Epilepsy,> 4 years,"Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy",CCCC1CC(=O)N(C(CC)C(N)=O)C1,1
Buccolam,midazolam,2011,no,Neurology,N- Neuropsychiatric,Epilepsy,3 months to < 18 years,"Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). BUCCOLAM must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. ",Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1
Cancidas,caspofungin acetate,2008,no,Infectious diseases,J- Antiinfectives, Aspergillosis Candidiasis,> 1 year,"Treatment of invasive candidiasis in adult or paediatric patients. Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.",CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(O)C(NCCN)NC(=O)C2C(O)CCN2C(=O)C(C(O)CCN)NC(=O)C(C(O)C(O)c2ccc(O)cc2)NC(=O)C2CC(O)CN2C(=O)C(C(C)O)NC1=O,1
Caprelsa,Vandetanib,2016,no,Oncology,L- Antineoplastic and immunomodulating,Thyroid Neoplasms,> 5 years,"Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.",COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,1
Cayston,aztreonam lysine,2012,yes,Infectious diseases,J- Antiinfectives,Cystic Fibrosis Respiratory Tract Infections,> 6 years,Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.,CC1C(=NC(=O)C(NOC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,0
Celsentri,maraviroc,2017,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 2 years,"CELSENTRI, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable",Cc1nnc(C(C)C)n1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1
Colobreathe,Colistimethate sodium,2012,no,Infectious diseases,J- Antiinfectives, Cystic Fibrosis,> 6 years,Colobreathe is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)O)C(=O)NC(C(=O)NC(CCNCS(=O)(=O)O)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCNCS(=O)(=O)O)NC(=O)C(CCNCS(=O)(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS(=O)(=O)O)NC1=O)C(C)O,1
Cystadrops,mercaptamine hydrochloride,2017,yes,Ophthalmology,Other ,Cystinosis,> 2 years,Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis,NCCS,1
Dectova,Zanamivir,2019,no,Infectious diseases,J- Antiinfectives,"Influenza, Human",> 6 months,"Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when: - The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or - Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. ",CC(=O)NC1C(N=C(N)N)C=C(C(=O)O)OC1C(O)C(O)CO,1
Deltyba,Delamanid,2020,yes,Infectious diseases,J- Antiinfectives,"Tuberculosis, Multidrug-Resistant", children with a body weight of at least 30 kg,"Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents and children with a body weight of at least 30 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability",CC1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1,1
Dificlir,fidaxomicin,2015,no,alimentary,A- Alimentary/Metabolism,Clostridium Infections,all ages,DIFICLIR film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg DIFICLIR granules for oral suspension is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age,CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)OC1C(C)OC(OCC2=CC=CCC(O)C(C)=CC(CC)C(OC3OC(C)(C)C(OC(=O)C(C)C)C(O)C3O)C(C)=CC(C)=CCC(C(C)O)OC2=O)C(OC)C1O,1
Ecalta,anidulafungin,2020,no,Infectious diseases,J- Antiinfectives,Candidiasis,> 1 month,Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years,CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(C(C)O)NC(=O)C(C(O)C(O)c5ccc(O)cc5)NC(=O)C5CC(O)CN5C(=O)C(C(C)O)NC4=O)cc3)cc2)cc1,1
Edurant,rilpivirine hydrochloride,2015,no,Infectious diseases,J- Antiinfectives, HIV Infections,> 12 years,"EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients 12 years of age and older with a viral load ≤ 100,000 HIV-1 RNA copies/ml. As with other antiretroviral medicinal products, genotypic resistance testing should guide the use of EDURANT.",Cc1cc(C=CC#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,1
ellaOne,ulipristal,2009,no,Genito urinary system and sex hormones,G- Genitourinary,"Contraception, Postcoital",adolescent,"ulipristal acetate for emergency contraception is suitable for any woman of child bearing age, including adolescents",CC(=O)C1(O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(c3ccc(N(C)C)cc3)CC21C,1
Forxiga,dapagliflozin propanediol monohydrate,2019,no,"Endocrinology, -gynacology-fertility-metabolism",A- Alimentary/Metabolism,nd,>10,Forxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes,CCOc1ccc(Cc2cc(C3OC(CO)C(O)C(O)C3O)ccc2Cl)cc1,1
Fycompa,perampanel,2012,no,Neurology,N- Neuropsychiatric,"Epilepsies, Partial",> 4 years,Fycompa (perampanel) is indicated for the adjunctive treatment of - partial-onset seizures (POS) with or without secondarily generalised seizures in patients from 4 years of age and older. - primary generalised tonic-clonic (PGTC) seizures in patients from 7 years of age and older with idiopathic generalised epilepsy (IGE),N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,1
Galafold,migalastat hydrochloride,2016,yes,Alimentary tract and metabolism,A- Alimentary/Metabolism,Fabry Disease,> 16 years,Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation,OCC1NCC(O)C(O)C1O,1
Genvoya,"elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide",2015,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 12 years at least 35 kg > 6 years at least 25 kg,"Genvoya is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows: • In adults and adolescents aged from 12 years and with body weight at least 35 kg • In children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.",CC(C)OC(=O)C(C)NP(=O)(COC(C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,1
Gilenya,fingolimod hydrochloride ,2018,no,Immunology,L- Antineoplastic and immunomodulating,Multiple Sclerosis,> 10 years,"Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older: - Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1). or - Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.",CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1
Inovelon,Rufinamide,2007,yes,Neurology,N- Neuropsychiatric,Epilepsy,> 1 year,Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 year of age and older.,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,1
Intelence,Etravirine,2012,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 2 years,"INTELENCE, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and in antiretroviral treatment-experienced paediatric patients from 2 years of age",Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br,1
Invega,paliperidone,2014,no,Neurology,N- Neuropsychiatric,Schizophrenia,> 15 years,Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,1
Isentress,Raltegravir,2012,no,Infectious diseases,J- Antiinfectives,HIV Infections,all ages,"ISENTRESS 600 mg film-coated tablets is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, and paediatric patients weighing at least 40 kg",Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1
Ivemend,fosaprepitant,2018,no,ALIMentary,A- Alimentary/Metabolism,Cancer Vomiting,> 6 months,Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older,CC(OC1OCCN(Cc2n[nH]c(=O)[nH]2)C1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1
Januvia,sitagliptin,2020,no,alimentary and metabolism,A- Alimentary/Metabolism,nd,nd,_PIP negative outcome,NC(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1
Kaletra,"lopinavir, ritonavir",2017,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 14 days,"Kaletra (oral solution) is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older. Kaletra (tablets) is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years. ",CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1
Kigabeq,vigabatrin,2018,no,Neurology,N- Neuropsychiatric,"Spasms, Infantile Epilepsies, Partial",1 month to 7 years,"Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for: - Treatment in monotherapy of infantile spasms (West's syndrome). - Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.",C=CC(N)CCC(=O)O,1
Kuvan,Sapropterin dihydrochloride,2008,yes,Alimentary tract and metabolism,A- Alimentary/Metabolism,Phenylketonurias, all ages,Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment. Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment.,CC(O)C(O)C1CNc2[nH]c(N)nc(=O)c2N1,1
Latuda,lurasidone,2020,no,Psychiatry ,N- Neuropsychiatric,Schizophrenia,> 13 years ,Latuda is indicated for the treatment of schizophrenia in adults and adolescent aged 13 years and over.,Oc1c2c(c(O)n1CC1CCCCC1CN1CCN(c3nsc4ccccc34)CC1)C1CCC2C1,1
Mimpara,cinacalcet hydrochloride,2017,no,Endocrinology,H- Systemic Hormones ,Hyperparathyroidism,> 3 years,"Secondary hyperparathyroidism Paediatric population Treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy  Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate  ",CC(NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1
Modigraf,tacrolimus,2014,no,Immunology-Rheumatology-Transplantation,L- Antineoplastic and immunomodulating,Graft Rejection,paediatric patients,"Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other  immunosupressive medicinal products in adult and paediatric patients. ",C=CCC1=CC(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC,1
Mozobil,Plerixafor,2019,yes,Oncology,L- Antineoplastic and immunomodulating,Multiple Myeloma Hematopoietic Stem Cell Transplantation Lymphoma,> 1 year,"Paediatric patients (1 to less than 18 years): Mozobil is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either: - pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or - who previously failed to collect sufficient haematopoietic stem cells ",c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,1
Orfadin,nitisinone,2015,yes,"Endocrinology, -gynacology-fertility-metabolism",A- Alimentary/Metabolism,Tyrosinemias,"all ages, dosage for weight",Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.,O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-],1
Orkambi,"Lumacaftor, ivacaftor",2015,no,Respiratory ,R- Respiratory,Cystic Fibrosis,> 2 years,Orkambi tablesis indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene. Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene,CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O,0
Orphacol,cholic acid,2013,yes,Gastroentology-Hepatology,A- Alimentary/Metabolism,"Digestive System Diseases Metabolism, Inborn Errors",> 1 month,"Orphacol is indicated for the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged 1 month to 18 years and adults.",CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,1
Pifeltro,Doravirine,2019,no,Infectious diseases,J- Antiinfectives,nd,>12,"Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV-1 without past or present evidence of resistance to the NNRTI class ",Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O,1
Plavix,Clopidogrel,2011,no,Cardiovascular disease,C- Cardiovascular,nd,nd,_PIP negative outcome,COC(=O)C(c1ccccc1Cl)N1CCc2sccc2C1,1
Pradaxa,Dabigatran etexilate mesilate,2011,no,Cardiovascular disease,C- Cardiovascular,nd,nd,Treatment of VTE and prevention of recurrent VTE in paediatric patients,CCCCCCOC(=O)N=C(N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1
Prezista,darunavir,2009,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 3 years,"Oral solution: PREZISTA, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. PREZISTA, co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). film-coated tablets 75-150-600: PREZISTA, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection. PREZISTA 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:  For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.  For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. film-coated tablets 400-800: PREZISTA, co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). PREZISTA 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:  antiretroviral therapy (ART)-naïve.  ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106 /L. In deciding to initiate treatment with PREZISTA in such ART-experienced patients, genotypic testing should guide the use of PREZISTA",CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OC1COC2OCCC12)S(=O)(=O)c1ccc(N)cc1,1
Procoralan,ivabradine,2015,no,Cardiovascular disease,C- Cardiovascular,nd,nd,_PIP negative outcome,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)CC1Cc3cc(OC)c(OC)cc31)CC2,1
Ravicti,glycerol phenylbutyrate,2015,yes,Alimentary tract and metabolism,A- Alimentary/Metabolism,"Urea Cycle Disorders, Inborn",all ages,"RAVICTI is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) in all ages patients who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).",O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1,1
Relvar Ellipta,"fluticasone furoate, vilanterol",2013,no,Respiratory ,R- Respiratory,Pulmonary Disease,> 12 years,Asthma Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists. • patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.,CC1CC2C3CC(F)C4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(OC(=O)c1ccco1)C(=O)SCF,1
Resolor,Prucalopride succinate,2015,no,Alimentary,A- Alimentary/Metabolism,nd,nd,_PIP negative outcome,COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,1
Revatio,sildenafil,2011,yes,Genito urinary system and sex hormones,G- Genitourinary,"Hypertension, Pulmonary",> 1 year,Paediatric population: Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1
Revolade,Eltrombopag,2016,yes,Haematology,B - Blood and blood forming organs,"Purpura, Thrombocytopenic, Idiopathic",> 1 year,"Revolade is indicated for the treatment of patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).",Cc1ccc(-n2[nH]c(C)c(N=Nc3cccc(-c4cccc(C(=O)O)c4)c3O)c2=O)cc1C,1
Reyataz,atazanavir sulfate,2016,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 6 years (capsules) > 3 months (oral powder),"REYATAZ capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. REYATAZ oral powder, co-administered with low dose ritonavir, is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected paediatric patients at least 3 months of age and weighing at least 5 kg. Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). The choice of REYATAZ in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history. ",COC(=O)NC(C(=O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)C(NC(=O)OC)C(C)(C)C)C(C)(C)C,1
Rinvoq,Upadacitinib,2019,no,Immunology-Rheumatology-Transplantation,L- Antineoplastic and immunomodulating,nd,>12,RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.,CCC1CN(C(=O)NCC(F)(F)F)CC1c1cnc2cnc3[nH]ccc3n12,1
Rozlytrek,Entrectinib,2020,no,Oncology,L- Antineoplastic and immunomodulating,"Cancer Carcinoma, Non-Small-Cell Lung",> 12 years,"Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and • who have not received a prior NTRK inhibitor • who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.",CN1CCN(c2ccc(C(=O)Nc3[nH]nc4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,1
Sirturo,bedaquiline fumarate,2019,yes,Infectious diseases,J- Antiinfectives,"Tuberculosis, Multidrug-Resistant",> 12 years  weighing at least 30 kg,SIRTURO is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability,COc1nc2ccc(Br)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,0
Sivextro,tedizolid phosphate,2020,no,Infectious diseases,J- Antiinfectives,"Soft Tissue Infections Skin Diseases, Bacterial",> 12 years,Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents 12 years of age and older.,Cn1nnc(-c2ccc(-c3ccc(N4CC(CO)OC4=O)cc3F)cn2)n1,1
Slenyto,melatonin,2018,no,Neurology,N- Neuropsychiatric,Sleep Initiation and Maintenance Disorders Autistic Disorder,> 2 years,"Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. ",COc1ccc2[nH]cc(CCNC(C)=O)c2c1,1
Sovaldi,Sofosbuvir,2017,no,Infectious diseases,J- Antiinfectives,"Hepatitis C, Chronic",> 3 years,Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above,CC(C)OC(=O)C(C)NP(=O)(OCC1OC(n2ccc(=O)[nH]c2=O)C(C)(F)C1O)Oc1ccccc1,1
Sprycel,dasatinib,2018,yes,Oncology,L- Antineoplastic and immunomodulating,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell ",> 1 year,SPRYCEL is indicated for the treatment of paediatric patients with: film-coated tablets  - newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.  - newly diagnosed Ph+ ALL in combination with chemotherapy.   powder for oral suspension  - newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. - newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy. ,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0
Stribild,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate",2017,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 12 years,Stribild is also indicated for the treatment of HIV-1 infection in adolescents aged 12 to < 18 years weighing ≥ 35 kg who are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate (TDF) ,CC(C)OC(=O)OCOP(=O)(COC(C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1
Sutent,Sunitinib,2018,yes,Oncology,L- Antineoplastic and immunomodulating,nd,nd,_PIP negative outcome,C=c1c(C(=O)NCCN(CC)CC)c(C)[nH]c1=Cc1c(O)[nH]c2ccc(F)cc12,1
Sycrest,asenapine (as maleate) ,2015,no,Psychiatry ,N- Neuropsychiatric,nd,nd,_PIP negative outcome,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1,1
Tamiflu,Oseltamivir (phosphate),2020,no,antiviral,J- Antiinfectives,"Influenza, Human",all ages including full term neonates,"Treatment of influenza: Tamiflu is indicated in adults and children including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. Prevention of influenza - Post-exposure prevention in individuals 1 year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - The appropriate use of Tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older. - Tamiflu is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak. Tamiflu is not a substitute for influenza vaccination: The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Decisions regarding the use of oseltamivir for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses, available information on influenza drug susceptibility patterns for each season and the impact of the disease in different geographical areas and patient populations.",CCOC(=O)C1=CC(OC(CC)CC)C(NC(C)=O)C(N)C1,1
Tasigna,nilotinib,2017,yes,Oncology,L- Antineoplastic and immunomodulating,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",Paediatric patients,"Tasigna is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, - paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.",Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1
Tivicay,dolutegravir,2014,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 4 week at least 3 kg > 6 years at least 14 kg,"Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age or older and weighing at least 14 kg. Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults,  adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.",CC1CCOC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,1
Tobi Podhaler,Tobramycin,2011,yes,Infectious diseases,J- Antiinfectives, Respiratory Tract Infections Cystic Fibrosis,> 6 years,TOBI Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis.,NCC1OC(OC2C(N)CC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)C(N)CC1O,1
Tracleer,Bosentan,2009,yes,Cardiovascular disease,C- Cardiovascular,"Hypertension, Pulmonary",> 1 year,Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity- posology available,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1
Translarna,Ataluren,2014,yes,Musculo-skeletal system,M- Musculoskeletal ,"Muscular Dystrophy, Duchenne",> 2 years,"Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testin",O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,1
Travatan,travoprost,2014,no,Ophthalmology,Other ,Ocular Hypertension Glaucoma,> 2 months ,Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.,CC(C)OC(=O)CCCC=CCC1C(O)CC(O)C1C=CC(O)COc1cccc(C(F)(F)F)c1,1
Trecondi,Treosulfan,2019,yes,Oncology,L- Antineoplastic and immunomodulating,Hematopoietic Stem Cell Transplantation,> 1 month  ,"Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases. ",CS(=O)(=O)OCC(O)C(O)COS(C)(=O)=O,1
Tybost,cobicistat,2020,no,Infectious diseases,J- Antiinfectives,HIV Infections,> 12 years,Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older: • weighing at least 35 kg co-administered with atazanavir or • weighing at least 40 kg co-administered with darunavir.,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,1
Tygacil,Tigecycline,2015,no,Infectious diseases,J- Antiinfectives,"Soft Tissue Infections Bacterial Infections Skin Diseases, Bacterial",> 8 years,"Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: - Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections - Complicated intra-abdominal infections (cIAI). Tygacil should be used only in situations where other alternative antibiotics are not suitable",CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1CC1CC3C(N(C)C)C(=O)C(C(N)=O)C(=O)C3(O)C(=O)C1C2=O,1
Velphoro,Sucroferric oxyhydroxide,2020,no,Uro-nephrology,G- Genitourinary,Hyperphosphatemia Renal Dialysis,> 2 years,Velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m²) or with CKD on dialysis.,OCC1OC(OC2(CO)OC(CO)C(O)C2O)C(O)C(O)C1O,1
Verkazia,ciclosporin,2018,yes,Ophthalmology,Other ,Conjunctivitis Keratitis,> 4 to 18 years,Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. ,CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,1
Vfend,voriconazole,2014,no,Infectious diseases,J- Antiinfectives,Aspergillosis Candidiasis Mycoses,> 2 years,"Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis",CC(c1ncncc1F)C(O)(Cn1cncn1)c1ccc(F)cc1F,1
Vimpat,lacosamide,2011,no,Neurology,N- Neuropsychiatric,Epilepsy,> 4 years,"Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy",COCC(NC(C)=O)C(=O)NCc1ccccc1,1
Viramune,nevirapine,2011,no,Infectious diseases,J- Antiinfectives,HIV Infections,all ages,"Tablets and oral suspension: Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age. 50- and 100-mg prolonged-release tablets: Viramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescents and children three years and above and able to swallow tablets. 100 and 400-mg prolonged-release tablets: Viramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents and children three years and above and able to swallow tablets.",Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1
Vitrakvi,larotrectinib sulfate,2019,no,Oncology,L- Antineoplastic and immunomodulating,Abdominal Neoplasms,> 1 month,"VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, - who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and - who have no satisfactory treatment options",O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,1
Votrient,pazopanib,2020,no,Oncology ,L- Antineoplastic and immunomodulating,nd,nd,_PIP negative outcome,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,1
Votubia,everolimus,2011,yes,Immunology,L- Antineoplastic and immunomodulating,Tuberous Sclerosis,> 1 year (SEGA associated TCS) > 2 years (TSC),"Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Votubia is indicated for the treatment of adult and paediatric patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease‑related symptoms, has not been demonstrated. Refractory seizures associated with tuberous sclerosis complex (TSC): Votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC).",COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,1
Xagrid,Anagrelide,2014,yes,Haematology-Hemostaseology,B - Blood and blood forming organs,nd,nd,_PIP negative outcome,Oc1cn2c(n1)Nc1ccc(Cl)c(Cl)c1C2,1
Xarelto,rivaroxaban,2013,no,Haematology,B - Blood and blood forming organs,nd,all ages,Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.,O=C(NCC1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1
Zavicefta,"avibactam sodium, ceftazidime pentahydrate",2020,no,Infectious diseases,J- Antiinfectives,"Pneumonia, Bacterial Soft Tissue Infections Pneumonia Urinary Tract Infections Gram-Negative Bacterial Infections",> 3 months,"Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:  Complicated intra-abdominal infection (cIAI)  Complicated urinary tract infection (cUTI), including pyelonephritis  Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents.",CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)c1csc(N)n1)C(=O)O,0
Zebinix,eslicarbazepine acetate,2016,no,Neurology,N- Neuropsychiatric,Epilepsy,> 6 years,"Zebinix is indicated as: - adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.",CC(=O)OC1Cc2ccccc2N(C(N)=O)c2ccccc21,1
Zinforo,Ceftaroline fosamil,2016,no,Infectious diseases,J- Antiinfectives,"Community-Acquired Infections Pneumonia Skin Diseases, Infectious",all ages,"Zinforo is indicated for the treatment of the following infections in neonates, infants, children,adolescents and adults: Complicated skin and soft tissue infections (cSSTI) Community-acquired pneumonia (CAP) ",CCON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CSC12)c1nsc(NP(=O)([O-])O)n1,0
Zoely,"Nomegestrol acetate, estradiol",2011,no,Endocrinology,H- Systemic Hormones ,nd,nd,n.d.,CC(=O)C1(O)CCC2C3=CC(C)=C4CC(=O)CCC4C3CCC21C,1
Zometa,Zoledronic acid,2010,no,muscul skeletal,M- Musculoskeletal ,nd,nd,_PIP negative outcome,O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1
